[Cisapride: clinical experience in 1071 patients with non-ulcer dyspepsia or reflux symptoms].
Controlled studies showed that cisapride is effective in non-ulcer dyspepsia. Its prokinetic properties are not complicated by dopamine inhibition. In our study the dose of 5 mg t.i.d. was adequate for the treatment of patients with gastric symptoms, while for patients with reflux symptoms the preferred dose is 10 mg t.i.d. cisapride. The average improvement after 1 month of treatment was 68%. Additional medication with antacids was not of benefit. Side effects such as abdominal cramps or diarrhea were minimal (less than 4%). 1071 patients were selected according to the principles described by Talley et al. in 1987. This method was well accepted by investigators and patients and is recommended for similar studies.
Fehr
H F
HF
Gastroenterologische Abteilung, Kantonsspital Aarau.
D000863:Antacids / Q000627:therapeutic use; D020117:Cisapride; D004305:Dose-Response Relationship, Drug; D004415:Dyspepsia / Q000188:drug therapy*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*
D000863:Antacids; D010880:Piperidines; D012702:Serotonin Antagonists; D020117:Cisapride
Cisaprid: Erfahrung in der Praxis bei 1071 Patienten mit Non-Ulcer-Dyspepsie (NUD) oder Refluxsymptomatik.